CEAPRO INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.24 CAD | -7.69% |
|
-.--% | +26.32% |
| Sales 2021 | 17.2M 12.48M 1.04B | Sales 2022 | 18.84M 13.67M 1.14B | Capitalization | 46.16M 33.5M 2.8B |
|---|---|---|---|---|---|
| Net income 2021 | 2M 1.45M 121M | Net income 2022 | 4M 2.9M 243M | EV / Sales 2021 | 2.46 x |
| Net cash position 2021 | 5.13M 3.72M 311M | Net cash position 2022 | 11.19M 8.12M 679M | EV / Sales 2022 | 1.86 x |
| P/E ratio 2021 |
16.7
x | P/E ratio 2022 |
10.5
x | Employees | - |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 95.99% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -7.69% | ||
| Current month | +2.13% | ||
| 1 month | +4.35% | ||
| 3 months | +37.14% | ||
| 6 months | -31.43% | ||
| Current year | +26.32% |
1 week
0.24
0.26
1 month
0.230.26
Current year
0.150.27
1 year
0.150.64
3 years
0.150.82
5 years
0.140.98
10 years
0.092.47
| Managers | Title | Age | Since |
|---|---|---|---|
Gilles Gagnon
CEO | Chief Executive Officer | 70 | 01/07/01 |
| Director of Finance/CFO | - | 05/15/05 | |
Mitch Regnier
CTO | Chief Tech/Sci/R&D Officer | - | 01/23/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Gilles Gagnon
CEO | Chief Executive Officer | 70 | 01/07/01 |
Ulrich Kosciessa
BRD | Director/Board Member | - | 27/15/27 |
William Li
BRD | Director/Board Member | 61 | 20/14/20 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 29/24/29 | 0.26 | -.--% | 17,375 |
| 26/24/26 | 0.26 | +8.33% | 72,000 |
| 25/24/25 | 0.24 | -.--% | 47,300 |
| 24/24/24 | 0.24 | -.--% | 2,000 |
| 23/24/23 | 0.24 | -.--% | 9,645 |
Delayed Quote Toronto S.E., April 30, 2024 at 07:00 pm IST
More quotes
Ceapro Inc. is a Canada-based biotechnology company. The Company is involved in the development of extraction technology and the application of this technology to the production of extracts and active ingredients from oats and other renewable plant resources. Its primary business activities relate to the development and commercialization of natural products for personal care, cosmetic, human, and animal health industries using technology, natural, renewable resources, and developing products, technologies, and delivery systems. The Company's products include a commercial line of natural active ingredients, including beta glucan, avenanthramides (colloidal oat extract), oat powder, oat oil, oat peptides, and lupin peptides, a commercial line of natural anti-aging skincare products, utilizing active ingredients, including beta glucan and avenanthramides and veterinary therapeutic products, including an oat shampoo, an ear cleanser, and a dermal complex/conditioner.
Calendar
23/05/2024
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +26.32% | 14.91M | |
| +0.17% | 42.86B | |
| +10.92% | 42.74B | |
| +44.30% | 41.36B | |
| -6.20% | 27.68B | |
| +5.23% | 25.15B | |
| -24.79% | 18.63B | |
| +26.69% | 12.37B | |
| -3.13% | 11.92B | |
| +6.57% | 11.21B |
- Stock Market
- Equities
- CZO Stock
